WilliamTHarrisMD

Pediatric Pulmonology • Birmingham, AL

Assistant Professor, Pediatrics, University of Alabama School of Medicine

Join to view full profile

Dr. Harris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Harris' full profile

Already have an account?

Office
1600 7th Ave S
Suite 620 ACC
Birmingham, AL 35233
Phone+1 205-638-9583

Fax+1 205-975-5983

Education & Training

University of North Carolina HospitalsFellowship, Pediatric Pulmonology, 2004 - 2007
Johns Hopkins UniversityResidency, Pediatrics, 2000 - 2003
University of Texas Southwestern Medical SchoolClass of 1999

Certifications & Licensure

AL State Medical License 2008 - 2024
NC State Medical License 2004 - 2009
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Pulmonology

Publications & Presentations

PubMed

228 citations
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-ar...
Jane C. Davies, Steve Cunningham, William T. Harris, Allen Lapey, Warren E. Regelmann
The Lancet. Respiratory Medicine. 2016-02-01
95 citations
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).
Margaret Rosenfeld, Steve Cunningham, William T. Harris, Allen Lapey, Warren E. Regelmann
Journal of Cystic Fibrosis. 2019-11-01
176 citations
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Margaret Rosenfeld, Claire E. Wainwright, Mark Higgins, Linda T Wang, Charlotte M. McKee
The Lancet. Respiratory Medicine. 2018-07-01